Senores Pharmaceuticals IPO Details
| IPO Issue Open Date: | 20 December 2024 |
| IPO Issue Close Date: | 24 December 2024 |
| IPO Issue Price Band: | ₹372 to ₹391 Per Share |
| Face Value: | ₹10 Per Equity Share |
| IPO Issue Size: | ₹582.11 Crores | 1,48,87,723 shares |
| Fresh Issue: | ₹500 Crores | 1,27,87,723 shares |
| Offer for Sale: | ₹80.11 Crores | 1,27,87,723 shares |
| Issue Type: | Book Built Issue |
| IPO Listing At: | BSE & NSE |
| IPO Retail Quota: | Not more than 10% |
| QIB Quota: | Not more than 75% |
| NII Quota: | Not more than 15% |
| Employee Discount: | ₹[.] per share |
Senores Pharmaceuticals IPO Prospectus:
Checkout the Senores Pharmaceuticals IPO Prospectus of DRHP and RHP file.
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
Senores Pharmaceuticals IPO Dates Timeline
| Issue Open Date: | 20 December 2024 |
| Issue Close Date: | 24 December 2024 |
| Basis of Allotment Date: | 26 December 2024 |
| Refunds Initiation: | 27 December 2024 |
| Shares Credit in Demat: | 27 December 2024 |
| IPO Listing Date Detail: | 30 December 2024 |
Senores Pharmaceuticals IPO Market Lot
| Application | Lot Size, Shares and Price Details |
| Retail (Min) | 1 lots and 38 shares = ₹14,858 |
| Retail (Max) | 13 lots and 494 shares = ₹1,93,154 |
| S-HNI (Min) | 14 lots and 532 shares = ₹2,08,012 |
| B-HNI Minimum | 67 lots and 2,584 shares = ₹10,10,344 |
Senores Pharmaceuticals IPO GMP*
| GMP Date | GMP Today | Subject to Sauda | Kostak | Expected Gain |
| 26th Dec | ₹240 | ₹6,200 | ₹- | 61% |
| 25th Dec | ₹230 | ₹6,200 | ₹- | 59% |
| 24th Dec | ₹230 | ₹6,000 | ₹- | 59% |
| 21th Dec | ₹200 | ₹5,500 | ₹- | 51% |
| 20th Dec | ₹150 | ₹4,000 | ₹- | 38% |
| 19th Dec | ₹125 | ₹2,500 | ₹- | 32% |
| 18th Dec | ₹- | ₹- | ₹- | ₹- |
| 17th Dec | ₹- | ₹- | ₹- | -5% |
Check Live GMP
About Senores Pharmaceuticals
Senores Pharmaceutical is one of the leading firms for generic medicine, certified by global food and drug authorities. Moreover, nowadays they are committed to good quality and manufacturing products to create more demand in the global healthcare industry. They also have the aim of innovation, production, and manufacturing verticals and also have the vision to make more affordable and accessible healthcare, especially for varied types of products. Moreover, they are providing a dynamic strategy, offering them access to products that are good to go. Noticeably, they have the strength of identifying, producing, specialty, underpenetrated, and complex pharmaceutical products, and received the reliability of customers to choose them over and over. Further, the US and Canadian market is the current focus along with 43 countries that also feel their presence as well. The company also manufactures critical care injectables and active pharmaceutical ingredients (APIs).
Senores Pharmaceuticals IPO Strengths
- Ability to cater to the Regulated Markets through our US FDA approved formulation manufacturing facility in the US
- Distinct niche product portfolio built in a short span for Regulated Markets
- Long term marketing arrangements with pharmaceutical companies in the Regulated Markets
- Presence in the Emerging Markets with a strong product portfolio, including specialty or complex products
Objects of the IPO Issue
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
- Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary;
- Funding the working capital requirements of the Company;
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Senores Pharmaceuticals Company Financial Report
The company reported revenue of ₹217.34 crores in 2024 against ₹39.02 crores in 2023. The company reported a Loss of ₹32.71 crores in 2024 against a Profit of ₹8.43 crores in 2023.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹14.63 | ₹13.49 | ₹0.99 | ₹59.15 |
| 2023 | ₹39.02 | ₹26.58 | ₹8.43 | ₹131.05 |
| 2024 | ₹217.34 | ₹192.40 | ₹32.71 | ₹621.88 |
| September 2024 | ₹183.35 | ₹153.95 | ₹23.94 | ₹678.08 |
Senores Pharmaceuticals IPO Valuation – Key Performance Indicator
KPI as of March 31, 2024.
| KPI | Values |
| ROE: | 23.60% |
| ROCE: | 11.73% |
| EBITDA Margin: | 20.70% |
| PAT Margin: | 15.25% |
| Debt to equity ratio: | 1.07 |
| Earning Per Share (EPS): | ₹13.67 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 23.60% |
| Net Asset Value (NAV): | ₹66.96 |
Peer Group Comparison
The below peer comparison table’s data are showing as per the DRHP and RHP.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Ajanta Pharma Limited | 64.82 | 34.37 | 23.47% | 281.60 | 4208.71 Cr. |
| Alembic Pharmaceuticals Limited | 31.33 | 34.58 | 13.40% | 245.12 | 6228.63 Cr. |
| Caplin Point Laboratories Limited | 60.79 | 25.23 | 21.69% | 309.03 | 1694.10 Cr. |
| Gland Pharma Limited | 46.90 | 43.73 | 9.26% | 529.65 | 5664.72 Cr. |
| Strides Pharma Science Limited | (7.76) | NA | (4.44%) | 225.43 | 4051.12 Cr. |
Senores Pharmaceuticals IPO Registrar
Link Intime India Private Limited
Phone: +91 8108114949
E-mail: senorespharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/
Senores Pharmaceuticals IPO Lead Manager
- Equirus Capital Private Limited
- Ambit Private Limited
- Nuvama Wealth Management Limited
Senores Pharmaceuticals IPO allotment status noq on Link Intime website. Click on Link Intime IPO weblink to get allotment status.
Promoters of Senores Pharmaceuticals
- Swapnil Jatinbhai Shah
- Ashokkumar Vijaysinh Barot.
Company Address
Senores Pharmaceuticals Limited
1101 to 1103,
11th floor, South Tower, ONE 42
Opposite Jayantilal Park,
Ambali Bopal Road, Ahmedabad,
Ahmedabad, Gujarat,
India, 380054
Phone: +91 -79-29999857
Email: cs@senorespharma.com;
Website: www. senorespharma.com